Key result
Exosomes show significant clinical application potential as diagnostic biomarkers and drug delivery vehicles for doxorubicin-induced cardiotoxicity.
Why the study?
Doxorubicin chemotherapy causes cardiomyocyte death and cardiotoxicity, prompting the need for novel strategies such as exosomes for diagnosis and treatment.
This review highlights the potential of exosomes as both diagnostic biomarkers and therapeutic delivery vehicles to mitigate doxorubicin-induced cardiotoxicity.
Exosome research may inform doxorubicin cardiotoxicity mechanisms; leaves open clinical translation pending prospective trials.
Doxorubicin (DOX) is a kind of representative anthracyclines. It has greatly prolonged lifespan of cancer patients. However, a long course of DOX chemotherapy could induce various forms of deaths of cardiomyocytes, such as apoptosis, pyroptosis and ferroptosis, contributing to varieties of cardiac complications called cardiotoxicity. It has become a major concern considering the large number of cancer patients' worldwide and increased survival rates after chemotherapy. Exosomes, a subgroup of extracellular vesicles (EVs), are secreted by nearly all cells and consist of lipid bilayers, nucleic acids and proteins. They can serve as mediators between intercellular communication via the transfer of bioactive molecules from secretory to recipient cells, modulating multiple pathophysiological processes. It has been proven that exosomes in body fluids can serve as biomarkers for doxorubicin-induced cardiotoxicity (DIC). Moreover, exosomes have attracted considerable attention because of their capacity as carriers of certain proteins, genetic materials (miRNA and lncRNA), and chemotherapeutic drugs to decrease the dosage of DOX and alleviate cardiotoxicity. This review briefly describes the characteristics of exosomes and highlights their clinical application potential as diagnostic biomarkers and drug delivery vehicles for DIC, thus providing a strategy for addressing it based on exosomes.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2021) conducted a review in Doxorubicin-induced cardiotoxicity. Exosomes was evaluated. Exosomes show significant clinical application potential as diagnostic biomarkers and drug delivery vehicles for doxorubicin-induced cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: